Pay in 4 interest-free payments of $6.67 Learn more
Ships within 48 hours · Estimated delivery Aug 19 - Aug 24
3 Thus, the significant weight loss and metabolic benefits of GLP-1 RAs are partly due to neurological mechanisms that may have therapeutic implications beyond weight loss and diabetes management
This meta-analysis assessed the safety and effectiveness of combinations of SGLT2is + GLP-1RAs with a focus on their cardioprotective effects along with glucose-lowering ability in patients with type 2 diabetes mellitus (T2DM) in a real-world setting
Every fat-metabolism, NAD+, SIRT1 and lean-mass effect described above is preclinical (rodent or cell) only and should be read as a hypothesis, not an established human benefit
Here are some of the largest recent moves: LPL FINANCIAL LLC added 158,405 shares (+301.0%) to their portfolio in Q4 2024, for an estimated $2,776,839 CAPITAL MANAGEMENT CORP /VA removed 118,345 shares (-28.2%) from their portfolio in Q4 2024, for an estimated $2,074,587 ENVESTNET ASSET MANAGEMENT INC removed 76,629 shares (-34.4%) from their portfolio in Q4 2024, for an estimated $1,343,306 SUSQUEHANNA INTERNATIONAL GROUP, LLP added 71,979 shares (+128.3%) to their portfolio in Q4 2024, for an estimated $1,261,791 EAM INVESTORS, LLC added 60,243 shares (+inf%) to their portfolio in Q4 2024, for an estimated $1,056,059 683 CAPITAL MANAGEMENT, LLC added 49,500 shares (+inf%) to their portfolio in Q4 2024, for an estimated $867,735 RENAISSANCE TECHNOLOGIES LLC removed 47,300 shares (-5.7%) from their portfolio in Q4 2024, for an estimated $829,169 To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard
